New York State Teachers Retirement System Purchases 529 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

New York State Teachers Retirement System grew its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 43,847 shares of the specialty pharmaceutical company’s stock after purchasing an additional 529 shares during the period. New York State Teachers Retirement System owned approximately 0.07% of Jazz Pharmaceuticals worth $5,400,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. UMB Bank n.a. lifted its holdings in shares of Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 129 shares in the last quarter. Itau Unibanco Holding S.A. lifted its holdings in shares of Jazz Pharmaceuticals by 63.2% in the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after purchasing an additional 172 shares in the last quarter. GAMMA Investing LLC raised its holdings in Jazz Pharmaceuticals by 49.8% during the fourth quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock worth $76,000 after acquiring an additional 206 shares in the last quarter. Venturi Wealth Management LLC raised its holdings in Jazz Pharmaceuticals by 577.0% during the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after acquiring an additional 704 shares in the last quarter. Finally, Versant Capital Management Inc raised its holdings in Jazz Pharmaceuticals by 56.7% during the fourth quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock worth $119,000 after acquiring an additional 350 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on JAZZ shares. Robert W. Baird upped their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $140.00 to $175.00 in a report on Thursday, December 12th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. Royal Bank of Canada reiterated an “outperform” rating and set a $179.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Finally, Piper Sandler reissued an “overweight” rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. One investment analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $180.33.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the sale, the chief executive officer now owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders have sold 5,053 shares of company stock valued at $617,442. 4.20% of the stock is owned by insiders.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $136.84 on Friday. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $138.27. The stock’s 50 day moving average is $124.59 and its 200-day moving average is $117.82. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $8.27 billion, a price-to-earnings ratio of 19.27, a PEG ratio of 1.03 and a beta of 0.56.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.